Importantly, in contrast to our cohort, patients in both studies did not receive a mineralocorticoid receptor antagonist therapy [17] and only partly a beta-adrenergic blocking therapy [14], which is recommended according to current HF guidelines [8,9,18]. Here, NR3C2 is linked to hydrops fetalis.